Pricing Log in Create free account

Kura Oncology, Inc. (KURA) vs MoonLake Immunotherapeutics (MLTX)

Kura Oncology, Inc. and MoonLake Immunotherapeutics are both Biotechnology companies. Kura Oncology, Inc. and MoonLake Immunotherapeutics are of similar size ($873.2M and $862.9M). MoonLake Immunotherapeutics has the higher net margin (0.00% vs −384.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, MoonLake Immunotherapeutics leads on 7 and Kura Oncology, Inc. on 6.

Valuation

Metric KURA MLTX Biotechnology median
P/E n/m n/m 8.50
P/S 10.45 n/m 9.71
P/B 16.66 1.65 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 3.85 n/m 9.21
Earnings yield (37.11%) (40.21%) (33.15%)
Free cash flow yield (14.55%) (31.91%) (25.50%)

Profitability

Metric KURA MLTX Biotechnology median
Gross margin 99.35% 0.00% 65.16%
Operating margin (411.90%) 0.00% 0.00%
Net margin (384.30%) 0.00% 0.00%
Free cash flow margin (152.06%) 0.00% 0.00%
Return on equity (167.71%) (67.08%) (56.36%)
Return on assets (46.73%) (51.00%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KURA MLTX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (57.43%) (86.77%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KURA MLTX Biotechnology median
Debt to equity 0.20 0.23 0.00
Current ratio 4.73 12.56 4.72
Net debt to EBITDA 2.11 1.32 0.96

Dividend

Metric KURA MLTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KURA MLTX Biotechnology median
Market cap 862.92m 873.19m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack